ZA200303069B - 4-amino-quinazolines. - Google Patents
4-amino-quinazolines. Download PDFInfo
- Publication number
- ZA200303069B ZA200303069B ZA200303069A ZA200303069A ZA200303069B ZA 200303069 B ZA200303069 B ZA 200303069B ZA 200303069 A ZA200303069 A ZA 200303069A ZA 200303069 A ZA200303069 A ZA 200303069A ZA 200303069 B ZA200303069 B ZA 200303069B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- mono
- het
- hal
- coor
- Prior art date
Links
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 60
- 239000012453 solvate Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 208000007536 Thrombosis Diseases 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 9
- 229920000728 polyester Polymers 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- -1 benzo[1,3]dioxol-5-yl Chemical group 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000004956 cyclohexylene group Chemical group 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- FWMBEYDLDLJTDP-UHFFFAOYSA-N 2-iodoquinazoline Chemical compound C1=CC=CC2=NC(I)=NC=C21 FWMBEYDLDLJTDP-UHFFFAOYSA-N 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- 239000012320 chlorinating reagent Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- ZHQSBSGAHYOIQE-UHFFFAOYSA-N 2-bromoquinazoline Chemical compound C1=CC=CC2=NC(Br)=NC=C21 ZHQSBSGAHYOIQE-UHFFFAOYSA-N 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 230000000181 anti-adherent effect Effects 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010038563 Reocclusion Diseases 0.000 claims description 2
- 238000006619 Stille reaction Methods 0.000 claims description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 150000001499 aryl bromides Chemical class 0.000 claims description 2
- 150000001503 aryl iodides Chemical class 0.000 claims description 2
- 125000005620 boronic acid group Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000005661 deetherification reaction Methods 0.000 claims description 2
- 238000007336 electrophilic substitution reaction Methods 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- SDIOBNKHLKIWOP-UHFFFAOYSA-N 2,2-diethylpropane-1,3-diamine Chemical compound CCC(CC)(CN)CN SDIOBNKHLKIWOP-UHFFFAOYSA-N 0.000 claims 1
- XUWHHIHUAYRUBC-UHFFFAOYSA-N 7-chloro-n-(3-imidazol-1-ylpropyl)-2-(2-phenylethenyl)quinazolin-4-amine Chemical compound N=1C(C=CC=2C=CC=CC=2)=NC2=CC(Cl)=CC=C2C=1NCCCN1C=CN=C1 XUWHHIHUAYRUBC-UHFFFAOYSA-N 0.000 claims 1
- BEJVJQYTITXDAL-UHFFFAOYSA-N 7-chloro-n-(3-morpholin-4-ylpropyl)-2-(2-phenylethenyl)quinazolin-4-amine Chemical compound N=1C(C=CC=2C=CC=CC=2)=NC2=CC(Cl)=CC=C2C=1NCCCN1CCOCC1 BEJVJQYTITXDAL-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- QUSDDLACQBMMHN-UHFFFAOYSA-N n-[2-(4-aminophenyl)ethyl]-7-chloro-2-(2-phenylethenyl)quinazolin-4-amine Chemical compound C1=CC(N)=CC=C1CCNC1=NC(C=CC=2C=CC=CC=2)=NC2=CC(Cl)=CC=C12 QUSDDLACQBMMHN-UHFFFAOYSA-N 0.000 claims 1
- FQQUFGNEAPRUAU-UHFFFAOYSA-N n-[7-chloro-2-(2-phenylethenyl)quinazolin-4-yl]-n',n'-diethylethane-1,2-diamine Chemical compound N=1C2=CC(Cl)=CC=C2C(NCCN(CC)CC)=NC=1C=CC1=CC=CC=C1 FQQUFGNEAPRUAU-UHFFFAOYSA-N 0.000 claims 1
- QGWJWZPXFJFLFO-UHFFFAOYSA-N n-[7-chloro-2-(2-phenylethenyl)quinazolin-4-yl]-n',n'-diethylpropane-1,3-diamine Chemical compound N=1C2=CC(Cl)=CC=C2C(NCCCN(CC)CC)=NC=1C=CC1=CC=CC=C1 QGWJWZPXFJFLFO-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 6
- 230000002792 vascular Effects 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- 102000019997 adhesion receptor Human genes 0.000 description 3
- 108010013985 adhesion receptor Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 101000973200 Homo sapiens Nuclear factor 1 C-type Proteins 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 102100022162 Nuclear factor 1 C-type Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108010081391 Ristocetin Proteins 0.000 description 1
- 101000973172 Sus scrofa Nuclear factor 1 Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229950004257 ristocetin Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66611700A | 2000-09-20 | 2000-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200303069B true ZA200303069B (en) | 2004-07-19 |
Family
ID=24672900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200303069A ZA200303069B (en) | 2000-09-20 | 2003-04-17 | 4-amino-quinazolines. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20040044204A1 (zh) |
EP (1) | EP1318985A2 (zh) |
JP (1) | JP2004509875A (zh) |
KR (1) | KR20030061807A (zh) |
CN (1) | CN1474816A (zh) |
AU (1) | AU2002213923A1 (zh) |
BR (1) | BR0114021A (zh) |
CA (1) | CA2422560A1 (zh) |
HU (1) | HUP0302429A3 (zh) |
MX (1) | MXPA03002411A (zh) |
NO (1) | NO20031267L (zh) |
PL (1) | PL359918A1 (zh) |
WO (1) | WO2002024666A2 (zh) |
ZA (1) | ZA200303069B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60132484T2 (de) * | 2000-11-02 | 2009-01-15 | Nippon Shinyaku Co., Ltd. | Chinazolinderivate und -arzneimittel |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
AU2003255482A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US20050209438A1 (en) * | 2004-03-19 | 2005-09-22 | Browne Edward P | Starter feed stream acidification in DMC-catalyzed process |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
US7473884B2 (en) * | 2005-04-21 | 2009-01-06 | Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. | Orientation determination utilizing a cordless device |
KR100728763B1 (ko) * | 2005-12-13 | 2007-06-19 | 주식회사 에스티넷 | Pon 또는 aon 방식의 방송/통신 융합 ftth시스템 |
PL2473487T3 (pl) | 2009-09-03 | 2017-07-31 | Bristol-Myers Squibb Company | Chinazoliny jako inhibitory kanałów jonowych potasowych |
CN102146076B (zh) * | 2010-02-05 | 2013-12-25 | 陕西师范大学 | 苯胺喹唑啉衍生物及其制备方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US14679A (en) * | 1856-04-15 | Joel h | ||
US55514A (en) * | 1866-06-12 | Improved machine for tunneling rock | ||
US44442A (en) * | 1864-09-27 | Dayid nelson | ||
US3970648A (en) * | 1974-09-06 | 1976-07-20 | Diamond Shamrock Corporation | 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines |
US3973021A (en) * | 1974-09-06 | 1976-08-03 | Diamond Shamrock Corporation | 2-[2-(5-Nitro-2-furyl)vinyl]-4-(phydroxyanilino)quinazoline as a bactericide |
US3974277A (en) * | 1974-09-06 | 1976-08-10 | Diamond Shamrock Corporation | 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines as growth promotants and feed efficiency enhancing agents |
US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
MX9200299A (es) * | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
JP3531944B2 (ja) * | 1991-02-07 | 2004-05-31 | アベンティス・ファーマ・ソシエテ・アノニム | 新規のベンジル基で置換された窒素系二環式誘導体及びその製造方法 |
US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
US5598994A (en) * | 1995-06-29 | 1997-02-04 | Panduit Corp. | Stud engaging device |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
DE19608653A1 (de) * | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
PT912559E (pt) * | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
HU229864B1 (en) * | 1996-08-12 | 2014-10-28 | Mitsubishi Tanabe Pharma Corp | Use of amide compounds for the preparation of medicaments |
US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
WO1999009986A1 (fr) * | 1997-08-22 | 1999-03-04 | Kyowa Hakko Kogyo Co., Ltd. | Derives de 4-aminoquinazoline |
US20020025968A1 (en) * | 1998-04-15 | 2002-02-28 | Rifat Pamukcu | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US6890930B1 (en) * | 1999-09-28 | 2005-05-10 | 3-Dimensional Pharmaceuticals, Inc. | Quinazolinones |
DE60140545D1 (zh) * | 2000-03-31 | 2009-12-31 | Nippon Shinyaku Co Ltd |
-
2001
- 2001-09-17 AU AU2002213923A patent/AU2002213923A1/en not_active Abandoned
- 2001-09-17 PL PL01359918A patent/PL359918A1/xx unknown
- 2001-09-17 EP EP01982300A patent/EP1318985A2/en not_active Withdrawn
- 2001-09-17 MX MXPA03002411A patent/MXPA03002411A/es unknown
- 2001-09-17 CN CNA018190782A patent/CN1474816A/zh active Pending
- 2001-09-17 JP JP2002529076A patent/JP2004509875A/ja active Pending
- 2001-09-17 KR KR10-2003-7004020A patent/KR20030061807A/ko not_active Application Discontinuation
- 2001-09-17 CA CA002422560A patent/CA2422560A1/en not_active Abandoned
- 2001-09-17 WO PCT/EP2001/010704 patent/WO2002024666A2/en not_active Application Discontinuation
- 2001-09-17 BR BR0114021-3A patent/BR0114021A/pt not_active Application Discontinuation
- 2001-09-17 US US10/380,909 patent/US20040044204A1/en not_active Abandoned
- 2001-09-17 HU HU0302429A patent/HUP0302429A3/hu unknown
-
2003
- 2003-03-19 NO NO20031267A patent/NO20031267L/no not_active Application Discontinuation
- 2003-04-17 ZA ZA200303069A patent/ZA200303069B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR0114021A (pt) | 2003-08-19 |
NO20031267D0 (no) | 2003-03-19 |
PL359918A1 (en) | 2004-09-06 |
WO2002024666A2 (en) | 2002-03-28 |
CA2422560A1 (en) | 2002-03-28 |
MXPA03002411A (es) | 2003-06-19 |
WO2002024666A3 (en) | 2002-09-26 |
EP1318985A2 (en) | 2003-06-18 |
JP2004509875A (ja) | 2004-04-02 |
US20040044204A1 (en) | 2004-03-04 |
HUP0302429A3 (en) | 2004-01-28 |
HUP0302429A2 (hu) | 2003-10-28 |
CN1474816A (zh) | 2004-02-11 |
AU2002213923A1 (en) | 2002-04-02 |
NO20031267L (no) | 2003-05-19 |
KR20030061807A (ko) | 2003-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5254543A (en) | Sulphonylbenzyl-substituted pyridones which are angiotension II receptor antagonists | |
ZA200303069B (en) | 4-amino-quinazolines. | |
JP5917555B2 (ja) | ケモカイン受容体調節因子としてのリン酸誘導体 | |
JP2003500384A (ja) | Xa因子阻害剤 | |
ZA200303062B (en) | 4-amino-quinazolines. | |
ZA200006758B (en) | Substituted benzamides, their production and their use as cysteine protease inhibitors. | |
KR100510854B1 (ko) | 혈전성질환의치료를위한피롤리딘,피페리딘및헥사하이드로아제핀의카르복사미드유도체 | |
JP2003520197A (ja) | サイトカイン阻害活性をもつ化合物 | |
JP2001502691A (ja) | トロンビン阻害剤 | |
EA200500096A1 (ru) | Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ | |
CZ280760B6 (cs) | Nové pyrazinové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem | |
US6211181B1 (en) | 1-Benzenesulfonyl pyrrolidine derivatives as bradykinin receptor antagonists | |
KR100981593B1 (ko) | N-구아니디노알킬아미드, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
JP2003506432A (ja) | カルボン酸アミド、その調製法及び医薬組成物としてのその使用 | |
CZ300365B6 (cs) | Inhibitory faktoru VIIa, zpusob jejich prípravy a jejich použití | |
CN100415719C (zh) | 2,5-二取代的3-巯基戊酸 | |
RU2007128065A (ru) | Новые гетероарилацетамиды | |
KR20060021900A (ko) | 심혈관질환의 치료를 위한 ace 저해제로서의에날라프릴-니트로옥시유도체 유도체들 및 관련화합물 | |
EP1236712B1 (en) | Amidinophenylpyruvic acid derivative | |
US6890930B1 (en) | Quinazolinones | |
US7829566B2 (en) | 4-amino-quinazolines | |
EP1216235A1 (en) | Quinazolinones | |
NZ509170A (en) | Bispiperidines as antithrombotic agents | |
PT91545A (pt) | Processo para a preparacao de aminometil-peptideos, uteis como medicamentos | |
ZA200105191B (en) | Substituted benzo(de)isoquinoline-1,3-diones. |